Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council

https://doi.org/10.14412/2074-2711-2023-2-134-146

Abstract

In recent decades, there has been an increase in the prevalence and medical and social burden of osteoarthritis (OA) and nonspecific back pain in all countries of the world. The First Multidisciplinary Bilateral Russia-Uzbekistan Expert Council presented innovations in the prognosing, personalized prevention and adjuvant therapy of degenerative-dystrophic diseases of the joints and spine, the evidence base for the effectiveness and safety of the use of drugs that modify the course of OA (Disease-modifying osteoarthritis drugs, DMOADs): chondroitin sulfate, glucosamine sulfate, undenatured type II collagen for adjuvant pharmaconutraceutical support – prevention and adjuvant therapy (treatment) of OA and nonspecific lumbosacral pain.
The expert counsil resolution presents an optimized algorithm for the management, prevention and adjuvant therapy of OA and non-specific back pain, maintaining the function of healthy joints after intense physical activity with the inclusion of the drug Chondroguard solution for intra-articular and intramuscular administration (INN – chondroitin sulfate) and a new pharmaconutraceutical from the DMOADs group – TRIO trademark Chondroguard® (Chondroguard®TRIO).

About the Authors

Al. B. Danilov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

8, Trubetskaya St., Build. 2, Moscow 119991


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation

34A, Kashirskoe Shosse, Moscow 115522; 
2/1, Barrikadnaya St., Build. 1, Moscow 125993


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



Yo. N. Majidova
Tashkent Pediatric Medical Institute
Uzbekistan

223, Bogishamol St., Tashkent 100140


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



O. A. Gromova
Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation

44, Vavilova St., Build. 2, Moscow 119333


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



O. N. Tkacheva
Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

16, 1st Leonova St., Moscow 129226


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



I. V. Sarvilina
Medical Center Novomeditsina LLC
Russian Federation

74, Sotsialisticheskaya St., Rostov-on-Don 344002


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. Yu. Kochish
Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden
Russian Federation

8, Akademika Baykova St., St. Petersburg 195427


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. G. Nazarenko
N.N. Priorov National Medical Research Center of Traumatology and Orthopedics
Russian Federation

10, Priorova St., Moscow 127299


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



N. V. Zagorodniy
N.N. Priorov National Medical Research Center of Traumatology and Orthopedics
Russian Federation

10, Priorova St., Moscow 127299


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



T. B. Minasov
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation

3, Lenina St., Ufa 450008


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



L. I. Alekseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

34A, Kashirskoe Shosse, Moscow 115522


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. A. Taskina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

34A, Kashirskoe Shosse, Moscow 115522


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



Yu. V. Kotovskaya
Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

16, 1st Leonova St., Moscow 129226


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. N. Dudinskaya
Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

16, 1st Leonova St., Moscow 129226


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. V. Rozanov
Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

16, 1st Leonova St., Moscow 129226


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. Yu. Solovieva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Faculty of Additional Professional Education 

1, Ostrovityanova St., Moscow 117997


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



O. A. Shavlovskaya
International University of Restorative Medicine
Russian Federation

8, Furmanny Lane, Build. 2, Moscow 105062


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



M. N. Sharov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation

20, Delegatskaya St., Build. 1, Moscow 127473


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



P. R. Kamchatnov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

1, Ostrovityanova St., Moscow 117997


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. P. Rachin
National Association of Experts in Comorbid Neurology
Russian Federation

12, Bolshaya Ochakovskaya St., Build. 6, Moscow 119361


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. R. Barantsevich
Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation

6-8, L’va Tolstogo St., St. Petersburg 197022


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



D. A. Iskra
Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
Russian Federation

2, Litovskaya St., St. Petersburg 194100


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. Z. Yakupov
Neuroclinic of Professor Yakupov
Russian Federation

52, Dostoevskiy St., Kazan 420043


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



F. I. Devlikamova
Kazan State Medical Academy, branch of Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation

11, Mushtari St., Kazan 420012


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. E. Barulin
Volgograd State Medical University, Ministry of Health of Russia
Russian Federation

1, Pavshikh Bortsov Sq., Volgograd 400131


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



M. V. Nesterova
Ural State Medical University, Ministry of Health of Russia
Russian Federation

3, Repina St., Yekaterinburg 620028


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



T. G. Sakovets
Kazan State Medical University, Ministry of Health of Russia
Russian Federation

49, Butlerova St., Kazan 420012


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. N. Barinov
Medical Academy of JSC “MEDSI” Group of Companies”
Russian Federation

3A, Gruzinsky Lane, Moscow 123056


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



I. N. Dolgova
Stavropol State Medical University, Ministry of Health of Russia
Russian Federation

310, Mira St., Stavropol 355017


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



N. V. Zabolotskikh
Kuban State Medical University, Ministry of Health of Russia
Russian Federation

4, Mitrophan Sedin St., Krasnodar 350063


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



E. V. Zonova
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation

52, Krasny Prosp., Novosibirsk 630091


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



L. A. Shchepankevich
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation

52, Krasny Prosp., Novosibirsk 630091


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



V. A. Parfenov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine 

11, Rossolimo St., Build. 1, Moscow 119021


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



A. T. Dzhurabekova
Samarkand State Medical University
Uzbekistan

18 Amir Temur St., Samarkand 100400


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



S. Z. Khakimova
Samarkand State Medical University
Uzbekistan

18 Amir Temur St., Samarkand 100400


Competing Interests:

Publication of this article has been supported by Sotex PharmFirma. The article expresses the position of the authors, which may differ from that of Sotex PharmFirma. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.



References

1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.

2. Leifer V, Katz J, Losina E. The burden of OAhealth services and economics. Osteoarthritis Cartilage. 2022;30:10-6. doi: 10.1016/j.joca.2021.05.007

3. Felson D. The epidemiology of knee osteoarthritis: Results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum. 1990;20:42-50. doi: 10.1016/0049-0172(90)90046-i

4. Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):11-7. doi: 10.14412/ 1996-7012-2019-4-11-17 (In Russ.).

5. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018;46(1):32-9. doi: 10.18786/2072-0505-2018-46-1-32-39 (In Russ.).

6. Felson D, Lawrence R, Dieppe P, Hirsch R. Osteoarthritis: newinsights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-46. doi: 10.7326/0003-4819-133-8-200010170-00016

7. Pal C, Singh P, Chaturvedi S, et al. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50:518-22. doi: 10.4103/0019-5413.189608

8. Iagnocco A. Chapter 14 – Osteoarthritis. In: Wakefield RJ, D’Agostino MA, editors. Essential Applications of Musculoskeletal Ultrasound in Rheumatology. Philadelphia, PA: W.B. Saunders; 2010; P. 165-80. ISBN 978-1-4377-0127-2

9. Bagi C, Berryman E, Teo S, Lane N. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis Cartilage. 2017 Dec;25(12):2080-90. doi: 10.1016/j.joca.2017.08.013. Epub 2017 Sep 6.

10. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012 Jun;64(6):1697-707. doi: 10.1002/art.34453. Epub 2012 Mar 5.

11. Camarero-Espinosa S, Rothen-Rutishauser B, Foster EJ, Weder C. Articular cartilage: from formation to tissue engineering. Biomater Sci. 2016 May 26;4(5):734-67. doi: 10.1039/c6bm00068a. Epub 2016 Feb 29.

12. The Global Burden of Low Back Pain. IASP, 2021. Available from: https://www.iasppain.org/resources/fact-sheets/the-global-burdenoflow-back-pain

13. Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020 Mar;8(6):299. doi: 10.21037/atm.2020.02.175

14. Podchufarova EV, Yakhno NN. Bol’ v spine [Backache]. Moscow; 2010. 368 p. (In Russ.).

15. Bardin LD, King P, Maher CG. Diagnostic triage for low back pain: a practical approach for primary care. Med J Aust. 2017 Apr 3;206(6):268-73. doi: 10.5694/mja16.00828

16. Parfenov VA, Isaykin AI. Boli v poyasnichnoy oblasti. Biblioteka prakticheskogo vracha. Seriya “Nevrologiya” [Pain in the lumbar region. Library of the practical doctor. Series “Neurology”]. Moscow: MEDpressinform; 2018 (In Russ.).

17. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).

18. National Guideline Centre (UK). Low Back Pain and Sciatica in Over 16s: Assessment and Management. London: National Institute for Health and Care Excellence (NICE); 2016 Nov.

19. Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-30. doi: 10.7326/M16-2367. Epub 2017 Feb 14.

20. Parfenov VA, Yakhno NN, Davydov OS, et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 2):7-16. doi: 10.14412/2074-2711-2019-2S-7-16 (In Russ.).

21. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. BMJ. 2015 Feb 18;350:h444. doi: 10.1136/bmj.h444

22. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) EvidenceBased Clinical Guideline of Interventional Treatments for Low Back Pain. J Pain Res. 2022 Dec 6;15:3729-832. doi: 10.2147/JPR.S386879. eCollection 2022.

23. Davydov O, Pavlova L, Zhukov E. Facet syndrome. Vrach. 2015;26(10):8-14 (In Russ.).

24. Torshin IYu, Lila AМ, Zagorodniy NV, et al. Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):7-16. doi: 10.17749/2070-4909/farmakoekonomika.2023.158 (In Russ.).

25. Knoop J, van der Leeden M, Thorstensson CA, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2011 Nov;63(11):1535-42. doi: 10.1002/acr.20571

26. Deveza LA, Melo L, Yamato TP, et al. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. Osteoarthritis Cartilage. 2017 Dec;25(12):1926-41. doi: 10.1016/j.joca.2017.08.009. Epub 2017 Aug 25.

27. Van Spil WE, Bierma-Zeinstra SMA, Deveza LA, et al. A consensus-based framework for conducting and reporting osteoarthritis phenotype research. Arthritis Res Ther. 2020 Mar 20;22(1):54. doi: 10.1186/s13075-020-2143-0

28. Widera P, Welsing PMJ, Ladel C, et al. Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data. Sci Rep. 2020 May 21;10(1):8427. doi: 10.1038/s41598-020-64643-8

29. Bowes MA, Kacena K, Alabas OA, et al. Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis. 2021 Apr;80(4):502-8. doi: 10.1136/annrheumdis2020-217160. Epub 2020 Nov 13.

30. Lazzarini N, Runhaar J, Bay-Jensen AC, et al. A machine learning approach for the identification of new biomarkers for knee osteoarthritis development in overweight and obese women. Osteoarthritis Cartilage. 2017 Dec;25(12):2014-21. doi: 10.1016/j.joca.2017.09.001. Epub 2017 Sep 9.

31. Luo Y, Samuels J, Krasnokutsky S, et al. A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. J Orthop Traumatol. 2021 Mar 9;22(1):10. doi: 10.1186/s10195-021-00572-0

32. Oo WM, Little C, Duong V, Hunter DJ. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Des Devel Ther. 2021 Jul 6;15:2921-45. doi: 10.2147/DDDT.S295224

33. DePalma MJ, Ketchum JM, Queler ED, Trussell BS. Prospective pilot study of painful lumbar facet joint arthropathy after intra-articular injection of hylan G-F 20. PM R. 2009 Oct;1(10):908-15. doi: 10.1016/j.pmrj.2009.09.008

34. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012 Jun;4(3):167-80. doi: 10.1177/1759720X12437753

35. Honvo G, Bruyere O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, PlaceboControlled Trials. Adv Ther. 2019 May;36(5):1085-99. doi: 10.1007/s12325-019-00921-w. Epub 2019 Mar 16.

36. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2009 Feb;60(2):524-33. doi: 10.1002/art.24255

37. Sarvilina IV, Minasov TB, Lila AM, et al. On the efficacy of the parenteral form of highly purified chondroitin sulfate in the mode of perioperative preparation for total knee arthroplasty. RMJ. 2022;(7):7-16 (In Russ.).

38. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018 Dec 25;320(24):2564-79. doi: 10.1001/jama.2018.19319

39. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD005614. doi: 10.1002/14651858.CD005614.pub2

40. Wandel P, Juni B, Tendal E, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. doi: 10.1136/bmj.c4675

41. Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol. 2007 Feb;47(1):78-83. doi: 10.1016/j.yrtph.2006.07.004. Epub 2006 Aug 30.

42. Klein RG, Eek BC, O’Neill CW, et al. Biochemical injection treatment for discogenic low back pain: a pilot study. Spine J. 2003 MayJun;3(3):220-6. doi: 10.1016/s1529-9430(02)00669-1

43. Van Blitterswijk WJ, van de Nes JC, Wuisman PI. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report. BMC Complement Altern Med. 2003 Jun 10;3:2. doi: 10.1186/1472-6882-3-2. Epub 2003 Jun 10.

44. Torshin IYu, Lila AM, Naumov AV, et al. Metaanalysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):388-99 doi: 10.17749/2070-4909/farmakoekonomika.2020.066.30 (In Russ.).

45. Barulin AE, Kurushina OV. Chondroprotectors in the complex therapy back pain. RMJ. 2013;21(30):1543-45 (In Russ.).

46. Sarvilina IV, Danilov AB. Comparative analysis of the use of symptomatic slow acting drugs for osteoarthritis containing chondroitin sulfate or affecting its biosynthesis in patients with non-specific low back pain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(1):81-96. doi: 10.17116/jnevro202312301181 (In Russ.).

47. Bruyere O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord. 2008 Dec 16;9:165. doi: 10.1186/1471-2474-9-165

48. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002946. doi: 10.1002/14651858.CD002946.pub2

49. Naumov AV, Sharov MN, Khovasova NO, Prokofieva YuS. Results of the intermittent regimen of initial pain therapy with chondroitin sulfate and glucosamine sulfate for patients with osteoarthritis, back pain and comorbidity. RMJ. 2018;4(II):47-54 (In Russ.).

50. Sarvilina IV, Lila AM, Gromova OA. New composition of pharmaceutical nutraceutical for antigen-specific prevention and adjunctive therapy of musculoskeletal diseases. RMJ. 2023;(2):44-50 (In Russ.).

51. Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.

52. Prabhoo R, Billa G. Undenatured collagen type II for the treatment of osteoarthritis: A review. Int J Res Orthop. 2018;4:684-9. doi: 10.18203/issn.2455-4510

53. Lugo J, Saiyed Z, Lau F, et al. Undenatured type II collagen (UC-II®) for joint support: A randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013;10:48. doi: 10.1186/1550-2783-10-48

54. Crowley D, Lau F, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: A clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi: 10.7150/ijms.6.312

55. Yang W, Sun C, He SQ, Chen JY, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis-systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085-93. doi: 10.1007/s11606-021-06755-z

56. Arwenfeld M. New data about glucosamin sulphate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2005;43(4):76-80. doi: 10.14412/1995-4484-2005-622 (In Russ.).

57. Register J, Rovati L, Deroisy R, et al. Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomized double-blind placebo-controlled, prospective 3-year trials. Ann Rheum Dis. 2002;61(Suppl 1):60.

58. Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res. 2005 Nov;66(11):1870-6. doi: 10.2460/ajvr.2005.66.1870

59. Tat SK, Pelletier JP, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther. 2007;9(6):R117. doi: 10.1186/ar2325

60. Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis. 2008 Jun;67(6):735-40. doi: 10.1136/ard.2006.068882. Epub 2007 Jul 20.

61. Martel-Pelletier J, Kwan Tat S, Pelletier JP. Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S7-11. doi: 10.1016/j.joca.2010.01.015. Epub 2010 Apr 27.

62. Tong T, Zhao W, Wu YQ, et al. Chicken type II collagen induced immune balance of main subtype of helper T cells in mesenteric lymph node lymphocytes in rats with collagen-induced arthritis. Inflamm Res. 2010 May;59(5):369-77. doi: 10.1007/s00011-009-0109-4. Epub 2009 Oct 28.

63. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997 Jul;18(7):335-43. doi: 10.1016/s0167-5699(97)01053-0

64. Shek PN, Shephard RJ. Physical exercise as a human model of limited inflammatory response. Can J Physiol Pharmacol. 1998 May;76(5):589-97. doi: 10.1139/cjpp-76-5-589

65. Müller RD, John T, Kohl B, et al. IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-alpha in human articular chondrocytes in vitro. Cytokine. 2008 Dec;44(3):377-85. doi: 10.1016/j.cyto.2008.10.012. Epub 2008 Nov 20.

66. Van Meegeren ME, Roosendaal G, Jansen NW, et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage. 2012 Jul;20(7):764-72. doi: 10.1016/j.joca.2012.04.002. Epub 2012 Apr 11.

67. Gromova OA, Torshin IYu, Lila AM. About the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):122-30. doi: 10.14412/2074-2711-2022-6-122-130 (In Russ.).

68. Alekseeva LI, Anikin SG, Zaitseva EM, et al. Efficacy, tolerability and safety study of Chondrogard® in patients with osteoarthritis. RMJ. 2013;32:1624 (In Russ.).

69. Klinicheskiye rekomendatsii po diagnostike i lecheniyu pervichnogo osteoartrita (dlya spetsialistov pervichnogo zvena: vrach-terapevt, vrach obshchey praktiki): Proyekt [Clinical guidelines for the diagnosis and treatment of primary osteoarthritis (for primary care professionals: therapist, general practitioner): Project]. Moscow: Russian Scientific Medical Society of Therapists, Russian Association of Rheumatologists; 2022. Available from: https://www.rnmot.ru/public/uploads/ RNMOT/clinical/2022/Recommendations%20RNM OT%20OA_30082022.pdf (accessed 16.04.2023) (In Russ.).


Review

Views: 369


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)